A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Elizabeth R. Gerstner; Xiaobu Ye; Dan G. Duda; Michael A. Levine; Tom Mikkelsen; Thomas J. Kaley; Jeffrey J. Olson; Burt L. Nabors; Manmeet S. Ahluwalia; Patrick Y. Wen; Rakesh K. Jain; Tracy T. Batchelor; Stuart Grossman

doi:10.1093/NEUONC/NOV085

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Elizabeth R. Gerstner
, Xiaobu Ye
, Dan G. Duda
, Michael A. Levine
, Tom Mikkelsen
, Thomas J. Kaley
, Jeffrey J. Olson
, Burt L. Nabors
, Manmeet S. Ahluwalia
, Patrick Y. Wen
, Rakesh K. Jain
, Tracy T. Batchelor
, Stuart Grossman

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	17
DOIs	https://doi.org/10.1093/NEUONC/NOV085
State	Published - Oct 1 2015

Disciplines

Medicine and Health Sciences
Oncology
Pathology
Internal Medicine

Access to Document

10.1093/NEUONC/NOV085License: Unspecified

Cite this

@article{770f666d04824881b36a23f1bcd68299,

title = "A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma",

author = "Gerstner, \{Elizabeth R.\} and Xiaobu Ye and Duda, \{Dan G.\} and Levine, \{Michael A.\} and Tom Mikkelsen and Kaley, \{Thomas J.\} and Olson, \{Jeffrey J.\} and Nabors, \{Burt L.\} and Ahluwalia, \{Manmeet S.\} and Wen, \{Patrick Y.\} and Jain, \{Rakesh K.\} and Batchelor, \{Tracy T.\} and Stuart Grossman",

note = "The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is the only US FDA-approved drug for recurrent glioblastoma (GBM), but the duration of response is short with most patients relapsing within 4-5 months.",

year = "2015",

month = oct,

day = "1",

doi = "10.1093/NEUONC/NOV085",

language = "American English",

volume = "17",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

AU - Gerstner, Elizabeth R.

AU - Ye, Xiaobu

AU - Duda, Dan G.

AU - Levine, Michael A.

AU - Mikkelsen, Tom

AU - Kaley, Thomas J.

AU - Olson, Jeffrey J.

AU - Nabors, Burt L.

AU - Ahluwalia, Manmeet S.

AU - Wen, Patrick Y.

AU - Jain, Rakesh K.

AU - Batchelor, Tracy T.

AU - Grossman, Stuart

N1 - The anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is the only US FDA-approved drug for recurrent glioblastoma (GBM), but the duration of response is short with most patients relapsing within 4-5 months.

PY - 2015/10/1

Y1 - 2015/10/1

UR - https://academic.oup.com/neuro-oncology/article/17/10/1386/1046036

U2 - 10.1093/NEUONC/NOV085

DO - 10.1093/NEUONC/NOV085

M3 - Article

VL - 17

JO - Neuro-oncology

JF - Neuro-oncology

ER -

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Disciplines

Access to Document

Other files and links

Cite this